HK1164721A1 - Therapeutic uses of quinazolinedione derivatives - Google Patents

Therapeutic uses of quinazolinedione derivatives

Info

Publication number
HK1164721A1
HK1164721A1 HK12105551.6A HK12105551A HK1164721A1 HK 1164721 A1 HK1164721 A1 HK 1164721A1 HK 12105551 A HK12105551 A HK 12105551A HK 1164721 A1 HK1164721 A1 HK 1164721A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic uses
quinazolinedione derivatives
abbreviated
nervous system
medicament
Prior art date
Application number
HK12105551.6A
Other languages
English (en)
Inventor
Gilbert Marciniak
Jean-Francois Nave
Fabrice Viviani
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1164721A1 publication Critical patent/HK1164721A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK12105551.6A 2009-03-27 2012-06-07 Therapeutic uses of quinazolinedione derivatives HK1164721A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0901460A FR2943673B1 (fr) 2009-03-27 2009-03-27 Applications therapeutiques de derives de quinazolinedione
PCT/FR2010/050549 WO2010109148A1 (fr) 2009-03-27 2010-03-25 Applications therapeutiques de derives de quinazolinedione

Publications (1)

Publication Number Publication Date
HK1164721A1 true HK1164721A1 (en) 2012-09-28

Family

ID=41203772

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105551.6A HK1164721A1 (en) 2009-03-27 2012-06-07 Therapeutic uses of quinazolinedione derivatives

Country Status (31)

Country Link
US (1) US8748441B2 (hr)
EP (1) EP2411009B8 (hr)
JP (1) JP5654559B2 (hr)
KR (1) KR101686263B1 (hr)
CN (1) CN102448461B (hr)
AR (1) AR075955A1 (hr)
AU (1) AU2010227359B2 (hr)
BR (1) BRPI1014688A2 (hr)
CA (1) CA2756645A1 (hr)
CL (1) CL2011002382A1 (hr)
CO (1) CO6430429A2 (hr)
CY (1) CY1114400T1 (hr)
DK (1) DK2411009T3 (hr)
EA (1) EA023670B1 (hr)
ES (1) ES2411880T3 (hr)
FR (1) FR2943673B1 (hr)
HK (1) HK1164721A1 (hr)
HR (1) HRP20130538T1 (hr)
IL (1) IL215368A0 (hr)
MA (1) MA33218B1 (hr)
MX (1) MX2011010150A (hr)
NZ (1) NZ595405A (hr)
PL (1) PL2411009T3 (hr)
PT (1) PT2411009E (hr)
SG (1) SG174931A1 (hr)
SI (1) SI2411009T1 (hr)
SM (1) SMT201300067B (hr)
TW (1) TWI471313B (hr)
UY (1) UY32526A (hr)
WO (1) WO2010109148A1 (hr)
ZA (1) ZA201107009B (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2944206B1 (fr) * 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
JP2014504271A (ja) * 2010-11-08 2014-02-20 オメロス コーポレーション Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
RS58381B1 (sr) * 2012-05-07 2019-04-30 Omeros Corp Lečenje zavisnosti i poremećaja kontrole impulsa upotrebom pde7 inhibitora
WO2013177349A2 (en) * 2012-05-25 2013-11-28 Glaxosmithkline Llc Quinazolinediones as tankyrase inhibitors
WO2013184806A1 (en) 2012-06-05 2013-12-12 University Of Kansas Inhibitors of respiratory syncytial virus
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
AU2020284606B2 (en) * 2019-05-31 2023-01-19 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
RU2715884C1 (ru) * 2019-06-24 2020-03-04 федеральное государственное автономное образовательное учреждение высшего образования "Северо-Кавказский федеральный университет" 2-бензилпроизводное 4-(3Н)хиназолинона, обладающее анальгезирующим, противопаркинсоническим, антигипоксантным, транквилизирующим действием
KR102685058B1 (ko) * 2020-09-02 2024-07-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물
RU2758333C1 (ru) * 2021-03-22 2021-10-28 федеральное государственное автономное образовательное учреждение высшего образования "Северо-Кавказский федеральный университет" Диметоксибензилсульфопроизводное хиназолин-4(3Н)-она, обладающее анальгезирующей, противопаркинсонической, анксиолитической, психостимулирующей активностью
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX7829A (es) * 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
EP0825993A1 (en) * 1995-05-19 1998-03-04 Chiroscience Limited Xanthines and their therapeutic use
JP2002308774A (ja) * 2001-04-12 2002-10-23 Nippon Zoki Pharmaceut Co Ltd Ｉｖ型ホスホジエステラーゼ選択的阻害剤
EP1348701A1 (en) * 2002-03-28 2003-10-01 Warner-Lambert Company LLC (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors
CN1980913B (zh) * 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.

Also Published As

Publication number Publication date
NZ595405A (en) 2013-03-28
PL2411009T3 (pl) 2013-09-30
TWI471313B (zh) 2015-02-01
AR075955A1 (es) 2011-05-11
SG174931A1 (en) 2011-11-28
FR2943673A1 (fr) 2010-10-01
BRPI1014688A2 (pt) 2016-04-12
PT2411009E (pt) 2013-05-27
CL2011002382A1 (es) 2012-02-17
MX2011010150A (es) 2011-12-14
CY1114400T1 (el) 2016-08-31
UY32526A (es) 2010-10-29
AU2010227359B2 (en) 2016-08-04
MA33218B1 (fr) 2012-04-02
CN102448461A (zh) 2012-05-09
ES2411880T3 (es) 2013-07-09
KR20120003904A (ko) 2012-01-11
ZA201107009B (en) 2012-11-28
TW201038539A (en) 2010-11-01
HRP20130538T1 (en) 2013-07-31
CA2756645A1 (fr) 2010-09-30
DK2411009T3 (da) 2013-06-24
EP2411009A1 (fr) 2012-02-01
EP2411009B8 (fr) 2013-06-26
WO2010109148A1 (fr) 2010-09-30
IL215368A0 (en) 2011-12-29
EA201171172A1 (ru) 2012-04-30
JP2012521974A (ja) 2012-09-20
AU2010227359A1 (en) 2011-10-20
EA023670B1 (ru) 2016-06-30
SMT201300067B (it) 2013-09-06
JP5654559B2 (ja) 2015-01-14
US20120058987A1 (en) 2012-03-08
SI2411009T1 (sl) 2013-07-31
FR2943673B1 (fr) 2013-03-29
EP2411009B1 (fr) 2013-03-20
CN102448461B (zh) 2014-08-06
KR101686263B1 (ko) 2016-12-13
US8748441B2 (en) 2014-06-10
CO6430429A2 (es) 2012-04-30

Similar Documents

Publication Publication Date Title
HK1164721A1 (en) Therapeutic uses of quinazolinedione derivatives
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
IN2015DN01156A (hr)
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
IN2012DN01233A (hr)
UA98961C2 (uk) Похідні піразинону та їх застосування у лікуванні легеневих захворювань
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2012001070A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
GEP201706707B (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MY148948A (en) Catecholamine derivatives and prodrugs thereof
NZ700283A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
GB201209587D0 (en) Therapeutic compounds
GB201302704D0 (en) Therapeutic compounds
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX2013002956A (es) Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.
IN2013DN02555A (hr)
MX2011012524A (es) Inhibidores de proteina cinasa c-met.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170325